ANTICOV Trial Finds Nitazoxanide/Ciclesonide Drug Combination Does Not Reduce Hospitalisation Risk in Patients With Mild COVID-19

ANTICOV, News, ANTICOV, NCT04920838, Feb 2022
Progression -104% improvement lower risk ← → higher risk Nitazoxanide  ANTICOV  EARLY TREATMENT RCT Is early treatment with nitazoxanide + ciclesonide beneficial? RCT 1,148 patients in multiple countries Trial compares with paracetamol, results vs. placebo may differ Higher progression with treatment (not stat. sig., p=0.092) c19early.org ANTICOV, News, February 2022 0 0.5 1 1.5 2+ RR
RCT with 591 nitazoxanide/ciclesonide and 557 paracetamol patients, up to 7 days from onset, showing higher progression, without statistical significance.
risk of progression, 104.3% higher, RR 2.04, p = 0.09, treatment 16 of 591 (2.7%), control 7 of 557 (1.3%), adjusted per study, odds ratio converted to relative risk, SpO2 ≤93 or death, day 21, Table 13.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
ANTICOV et al., 28 Feb 2022, Randomized Controlled Trial, multiple countries, preprint, 1 author, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with ciclesonide) - results of individual treatments may vary, trial NCT04920838 (history) (ANTICOV).
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
Submit